Anti-Fungus Stock Surges After Warnings Over Drug-Resistant Strain
- Scynexis, a pharmaceutical company, jumped 74% over two days
- Rally follows CDC report about spread of Candida auris in US
Candida auris, a yeast that is resistant to most antifungal drugs.
Photographer: BSIP/Universal Images Group/Getty ImagesThis article is for subscribers only.
Scynexis Inc., a pharmaceutical company that develops antifungal medicines, notched its largest two-day surge ever on Wednesday following a report of the increasing threat of a drug-resistant fungus spreading in the US.
Shares have jumped 74% over the last two days after touching a record low on Friday. The New Jersey-based company closed at $2.00 a share, up about 28% on Wednesday after gaining more than 35% the day before.